Skip to content
Companies

Latigo Biotherapeutics

Non-opioid pain medicines

Raised to date

$50M

of $150M offered across 1 Form D filing

Still open
$100M
Investors
7
Last filed
Feb 13, 2025

About

Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of non-opioid pain medicines. Based in Thousand Oaks, CA, the company leverages advanced technologies, including artificial intelligence and machine learning, to create innovative treatments that address the unmet needs in pain management.

Latigo Biotherapeutics stands out by focusing on the fundamental mechanisms of pain transduction, offering patients safer alternatives to traditional pain management solutions while minimizing dependency risks.

Funding

  • EquityFiled Feb 13, 2025Form D
    $50M/ $150M

Product

LTG-001

Pharmaceuticals

LTG-001 is Latigo Biotherapeutics' lead candidate that aims to provide effective non-opioid pain relief. Successfully navigating Phase 1 clinical trials, it addresses the root causes of pain without the associated risks of addiction linked to opioid medications.

  • Targets fundamental mechanisms of pain transduction
  • Ensures rapid onset of action
  • Superior safety profile

Built for

Patients requiring pain management and healthcare providers

People on file